Literature DB >> 24390518

Clinical and radiological observations in a case series of 26 patients with fibrous dysplasia.

Malissa Dawn Thomsen1, Lars Rejnmark.   

Abstract

Fibrous dysplasia (FD) is a rare disease caused by a sporadic postzygotic missense mutation that leads to abnormal fibroblast proliferation, defective osteoblast differentiation, and increased bone resorption. It may affect one or several bones. Both the mono-ostotic and polyostotic types may be associated with hyperfunctional endocrinopathies and hyperpigmentation of the skin (café-au-lait spots) in the so-called McCune-Albright syndrome (MAS). Due to its rarity, only a few case series are available, making it difficult for most clinicians to judge the severity of the disease. To improve our knowledge of FD, we reviewed all cases of FD treated at our department of endocrinology. Among 26 patients, 17 (65 %) had polyostotic FD, with four being diagnosed with MAS. Patients with polyostotic FD were diagnosed at an earlier age (median 13, range 0.5-64 years) than patients with the mono-ostotic form (median 21, 1-70 years). Craniofacial bones were affected in 80 % of cases, and 66 % complained of bone pain at the affected site, with no difference between patients with mono- and polyostotic FD. Two patients with mono-ostotic and three with polyostotic FD had cranial nerve impairments. Fourteen underwent, at least, one surgery, six (67 %) with mono-ostotic and eight (47 %) with polyostotic FD. Most received treatment with bisphosphonates, but therapy did not result in any clear relief of symptoms or radiological improvements. In conclusion, bone pain is common in patients with FD. The severity of the disease depends on affected bones as mono-ostotic may be as debilitating as polyostotic FD. In our case series, bisphosphonate treatment did not show clear beneficial effects.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24390518     DOI: 10.1007/s00223-013-9829-0

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  10 in total

1.  Bisphosphonate-induced zebra lines in fibrous dysplasia of bone: histo-radiographic correlation in a case of McCune-Albright syndrome.

Authors:  Alessandro Corsi; Ernesto Ippolito; Pamela G Robey; Mara Riminucci; Alan Boyde
Journal:  Skeletal Radiol       Date:  2017-06-28       Impact factor: 2.199

2.  Our experience in the surgical management of craniofacial fibrous dysplasia: what has changed in the last 10 years?

Authors:  V Valentini; A Cassoni; V Terenzi; M Della Monaca; M T Fadda; O Rajabtork Zadeh; I Raponi; A Anelli; G Iannetti
Journal:  Acta Otorhinolaryngol Ital       Date:  2017-10       Impact factor: 2.124

3.  Value of 99mTc-MDP SPECT/CT and 18F-FDG PET/CT scanning in the evaluation of malignantly transformed fibrous dysplasia.

Authors:  Wei-Jun Wei; Zhen-Kui Sun; Chen-Tian Shen; Xin-Yun Zhang; Juan Tang; Hong-Jun Song; Zhong-Ling Qiu; Quan-Yong Luo
Journal:  Am J Nucl Med Mol Imaging       Date:  2017-07-15

4.  Continuous effect with long-term safety in zoledronic acid therapy for polyostotic fibrous dysplasia with severe bone destruction.

Authors:  Di Wu; Jie Ma; Suqing Bao; Haixia Guan
Journal:  Rheumatol Int       Date:  2014-09-18       Impact factor: 2.631

5.  A Rare Cause of Shoulder Pain: Monostotic Fibrous Dysplasia.

Authors:  Bayram Kelle; Aygül Polat Kelle; Kıvılcım Eren Erdoğan; Erkan Kozanoğlu
Journal:  Arch Rheumatol       Date:  2016-04-06       Impact factor: 1.472

Review 6.  Osteoclasts: more than 'bone eaters'.

Authors:  Julia F Charles; Antonios O Aliprantis
Journal:  Trends Mol Med       Date:  2014-07-06       Impact factor: 11.951

7.  Characteristics and Treatment Results of 5 Patients with Fibrous Dysplasia and Review of the Literature.

Authors:  Nilufer Ozdemir Kutbay; Banu Sarer Yurekli; Emine Kartal Baykan; Serap Baydur Sahin; Fusun Saygili
Journal:  Case Rep Endocrinol       Date:  2015-06-14

Review 8.  Clinical and translational pharmacological aspects of the management of fibrous dysplasia of bone.

Authors:  Marlous Rotman; Neveen Agnes Therese Hamdy; Natasha M Appelman-Dijkstra
Journal:  Br J Clin Pharmacol       Date:  2018-12-25       Impact factor: 4.335

9.  Response to Zoledronic Acid Infusion in Children With Fibrous Dysplasia.

Authors:  Sujit Kumar Tripathy; Shakti Swaroop; Sandeep Velagada; Debashree Priyadarshini; Rashmi Ranjan Das; Amit Kumar Satpathy; Kanhaiyalal Agrawal
Journal:  Front Pediatr       Date:  2020-11-24       Impact factor: 3.418

10.  Effect of Intranasal Calcitonin in a Patient with McCune-Albright Syndrome, Fibrous Dysplasia, and Refractory Bone Pain.

Authors:  Tayane Muniz Fighera; Poli Mara Spritzer
Journal:  Case Rep Endocrinol       Date:  2017-06-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.